P-084: Bone marrow of patients post ASCT, but not chemotherapy consolidation, contains expanded T cell receptor clonotypes that are present at diagnosis: results from the Phase 2 CARDAMON study
Kane Foster(London Cancer), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Daria Galas‐Filipowicz(CRUK Lung Cancer Centre of Excellence), Evie Fitzsimons, James D. Cavenagh(National Health Service), Benny Chain(University College Lahore), Lydia Lee(CRUK Lung Cancer Centre of Excellence), Tushhar Dadaga(Cancer Research UK), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Suzanne Byrne(Brigham and Women's Hospital), William W. Wilson(Dakota State University), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Elizabeth Philips, Reuben Benjamin(King's College London), Selina J Chavda(University College London), Michael Chapman(Dartmouth College)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605